hit counter
Alnylam Pharmaceuticals, Inc. (ALNY) Stock News Sentiment & Price - Sentifly
ALNY - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Alnylam Pharmaceuticals, Inc. (ALNY)

USA
Biotechnology
NASDAQ
ALNY Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ALNY Latest news
Business Wire
Neutral
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
2021-11-08 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-2, a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension. KARDIA-2 will evaluate the efficacy and safety of zilebesiran administered biannually as

Business Wire
Neutral
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
2021-11-05 13:30

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – that is being investigated for the treatment of patients of all ages with advanced primary hyperoxaluria type 1 (PH1). The clinical data were present

GuruFocus
Neutral
The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter
2021-11-03 16:14

The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.

Business Wire
Neutral
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
2021-11-01 16:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ranked third in Science's 2021 Top Employers Survey. The magazine's annual survey of more than 7,200 people in biotechnology, biopharmaceutical, pharmaceutical, and related industries determine the top 20 best employers, as well as reveals their driving characteristics. Alnylam's 2021 ranking marks the third consecutive year that it has placed withi

Forbes
Negative
What's Happening With Alnylam Stock?
2021-11-01 06:30

The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, plunged over 15% in yesterday's trading session, following its Q3 results, which were much lower than the Wall Street estimates. The company reported.

Zacks Investment Research
Negative
Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates
2021-10-29 12:14

Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021.

The Motley Fool
Negative
Why Alnylam Pharmaceuticals Stock Is Tanking This Week
2021-10-29 06:04

The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.

Seeking Alpha
Neutral
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q3 2021 Results - Earnings Call Transcript
2021-10-28 16:49

Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q3 2021 Results - Earnings Call Transcript

The Motley Fool
Negative
Why Alnylam Pharmaceuticals Is Crashing Today
2021-10-28 13:48

The company's earnings fell short of expectations and its CEO is leaving.

Zacks Investment Research
Negative
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates
2021-10-28 10:42

Alnylam (ALNY) delivered earnings and revenue surprises of -13.91% and -15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Loading more news...